The cabozantinib/nivolumab combination has been shown to be effective at improving survival in patients with metastatic clear cell renal cell carcinoma (RCC) in a phase 3 trial. This study, presented at the American Society for Clinical Oncology (ASCO) Annual Meeting held virtually over the weekend reports the results of a phase 2 trial of cabozantinib/nivolumab […]
Adjuvant therapy is medication that is given in addition to surgery (nephrectomy) to try to prevent the cancer from coming back. Adjuvant therapy can be used to kill any remaining microscopic cancer cells, or it can control the growth of any remaining cancer. Nephrectomy is the standard of care for renal cell carcinoma (RCC); however, […]
Circulating tumour cells in the blood of cancer patients are markers for a poor outcome (prognosis) in people with breast, colorectal, lung and prostate cancer. However, little data is available for renal cell carcinoma (RCC). This multicentre observational study looked at the link between the number of circulating tumour cells and survival in people with […]
Some very interesting work has been coming out of the Francis Crick Institute in London about the evolution of kidney tumours. The research is being led by Dr Samra Turajlic who also works at the Royal Marsden Hospital in London and is one of KCSN’s trustees. Here is her explanation of this very exciting work: […]
Recurrence occurs when cancer comes back after surgery, or after a period of time being cancer-free. For people with clear cell renal cell carcinoma (RCC), the most common type of kidney cancer, the recurrent cancer can spread and develop into metastatic disease, despite treatment. A new study from researchers at Columbia University in the USA […]
Research published in the journal Nature Ecology and Evolution led by scientists from the Francis Crick Institute, Royal Marsden, University College London and Cruces University Hospital has found that cells from different parts of kidney tumours behave differently. The researchers have discovered that cells from the centre of a kidney cancer tumour are the most […]
In this video interview from UroToday Dena Battle from KCCure, an American kidney cancer patient advocacy organisation, joins urologist Jaime Landman and oncologist Monty Pal to dispel common myths regarding the diagnosis and treatment of kidney cancer being observed in patient communities and to speak about what is driving this misinformation. Watch the video interview […]
In this study 15 years of data from a single hospital were assessed to look at the outcomes of people who had had surgery for localised renal cell carcinoma (RCC). Of the 1895 people who were assessed, 30 (1.6%) had a single local recurrence of their cancer without distant spread (metastases). In total, 26 of […]
Percutaneous microwave ablation uses thin needle-like electrodes that are passed through the skin (percutaneous) into the tumour to kill the cancer cells with microwaves. This is usually done under the guidance of ultrasound imaging. During this observational study the short- and long-term outcomes of 113 patients who had microwave ablation for small renal masses (stage […]
The pharmaceutical industry is dedicated to developing effective vaccines that benefit people’s health, the economy and society. Vaccination has saved more lives and prevented more serious diseases than any other advance in recent medical history. It has also enabled the economy to thrive and reduced the burden on the NHS. COVID-19 has shone a spotlight […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
